Abstract:Objective To compare the clinical effect of xiaochuanning granule on chronic persistent bronchial asthma based on Th1/Th2 immuno-balance. Methods From January 2018 to February 2019, 130 patients with chronic persistent bronchial asthma in our hospital were collected and randomly divided into control group (salmeterol and fluticasone propionate inhalation) and observation group (salmeterol and fluticasone propionate inhalation + xiaochuanning granule). The clinical effect was observed. The changes of Th1/CD4+, Th2/CD4+, Th1/Th2, related cytokines, such as interleukin (IL)-4, IL-12, IL-17, interferon-γ (IFN-γ), and nuclear transcription factors, such as T-box expressed in T cells (T-bet), GATA-binding protein 3 (GATA-3), retinoid related orphan nuclear receptor subfamily γt (ROR γt), fork-head box P3 (FoxP3) mRNAs, were compared between the two groups. Results After 12 months of treatment, the recovery rate of observation group were 32.31% (21/65), higher than that of control group (P < 0.05). Patients in both groups had lower Th2/CD4+(%), serum values of IL-4, IL-17 and GATA-3 mRNA, ROR γt mRNA than before treatment, while they had higher Th1/CD4+(%), Th1/Th2 ratio, the serum values of IL- 10, IFN-γ and T-bet mRNA, FoxP3 mRNA. The declined differences of Th2/CD4+(%), serum values of IL-4, IL- 17 and GATA-3 mRNA, ROR γt mRNA and the increased differences of Th1/CD4+(%), Th1/Th2 ratio, the serum values of IL-10, IFN-γ and T-bet mRNA, FoxP3 mRNA in observation group were higher than those in control group (P < 0.05). Conclusion The application of xiaochuanning granule in the treatment of chronic persistent bronchial asthma could effectively improve the clinical recovery by regulating Th1/Th2 immuno-balance, which would be recommended for an effective treatment.